Drug Profile
Research programme: oxazolidinone antibacterials - LegoChem Biosciences
Alternative Names: Arylamidoximes - LegoChem Biosciences; Arylhydroxamates - LegoChem Biosciences; Cyclic amidrazone antibacterials - LegoChem BioSciences; LCB 010062; LCB 010156; LCB 010180; LCB01-0183; LCB01-0339; LCB01-0343; LCB01-0347; LCB01-0647; LCB01-0676; LCB01-0687; LCB01-0699Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator LegoChem Biosciences
- Class Hydroxamic acids; Oxazolidinones; Oximes
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Gram-positive infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in South Korea
- 16 Jul 2016 No recent reports of development identified for preclinical development in Gram-positive-infections in South Korea
- 17 Sep 2011 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical studies in Bacterial infections presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2011) ,,